| Literature DB >> 26155403 |
Kevin Van der Jeught1, Sandra Van Lint1, Kris Thielemans1, Karine Breckpot1.
Abstract
The immunosuppressive tumor microenvironment (TME) is a major obstacle in cancer immunotherapy. Therefore, it has gained attention as a target site. mRNA emerged as a versatile drug class for cancer therapy. We reported that intratumoral administration of mRNA encoding the fusokine Fβ2 supports tumor-specific T-cell immunity. This study provides proof of concept of the use of mRNA to modulate the TME.Entities:
Keywords: CD8+ T cell; CTLs, cytotoxic T lymphocytes; DCs, dendritic cells; Fβ2, a fusokine consisting of IFNβ, fused to the ectodomain of the TGFβ receptor II; IFNβ; IMP, investigational medicinal product; MDSCs, myeloid-derived suppressor cells; TAAs, tumor-associated antigens; TGFβ ; TME, tumor microenvironment; TiDCs, tumor-infiltrating DCs; cancer; dendritic cell; fusokine; immunotherapy; intratumoral; mRNA; receptor II
Year: 2015 PMID： 26155403 PMCID： PMC4485825 DOI： 10.1080/2162402X.2015.1005504
Source DB: PubMed Journal: Oncoimmunology ISSN： 2162-4011 Impact factor: 8.110